RxDoctor Payments DataLook up a doctor →

Robert Feldman, MD

Geriatric Medicine · Laguna Hills, CANPI 1194805416

Payments from drug & device makers

$1,909,799in general payments, 2019–2025

Across 2,122 payments — averaging $900.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$846K
  • Amgen$523K
  • Eli Lilly$345K
  • Biogen$113K
  • Merck$57K
  • Lilly USA, LLC$13K
  • plus $13K from 13 others
$871in research payments, 2019–2025

Across 3 payments — averaging $290.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$871

What the payments were for

  • Consulting fees$13,7251%
  • Speaking & faculty fees$904,02178%
  • Travel & lodging$207,93618%
  • Food & beverage$34,3213%
  • Education$4700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,909,799 in reported general payments places this provider in the 95th percentile of 494 geriatric medicine providers in California.

See all geriatric medicine providers in California

Medicare billing

Part B allowed, 2024
$548,341
Medicare patients
248
Services billed
25,565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban107$87,056
EliquisApixaban63$59,099
ProliaDenosumab36$58,982
JanuviaSitagliptin Phosphate39$38,135
TymlosAbaloparatide11$31,364
EntrestoSacubitril/Valsartan19$21,610
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,253
MyrbetriqMirabegron17$14,977
Repatha SureclickEvolocumab13$10,340
Rivastigmine22$9,020
Risedronate Sodium95$7,759
Metoprolol Succinate449$7,600
Pantoprazole Sodium432$5,776
Memantine Hcl158$5,562
Rosuvastatin Calcium391$5,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$9,415$87,056107 claims
PfizerEliquis$23$59,09963 claims
AmgenProlia$523,356$58,98236 claims
MerckJanuvia$56,687$38,13539 claims
Radius Health, Inc.Tymlos$215$31,36411 claims
NovartisEntresto$56$21,61019 claims
GSKTrelegy Ellipta$846,368$21,25325 claims
Astellas Pharma US IncMyrbetriq$13$14,97717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 494 geriatric medicine providers in California.

Other geriatric medicine in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →